Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
Delcath Systems Inc (NASDAQ: DCTH) specializes in innovative liver cancer therapies through its proprietary drug-device combination. This page provides investors and medical professionals with direct access to all official company announcements, including clinical trial milestones, regulatory updates, and strategic partnerships.
Discover the latest developments in Delcath's hepatic delivery system and melphalan hydrochloride treatments. Our curated news collection features FDA communications, European commercialization progress, and peer-reviewed research findings – essential resources for understanding the company's position in interventional oncology.
Key updates on: Clinical trial phases | Regulatory approvals | Financial results | Medical conference presentations | Partnership announcements. Bookmark this page to monitor Delcath's advancements in targeted chemotherapy delivery and liver cancer treatment protocols.
Delcath Systems (Nasdaq: DCTH), an interventional oncology company focusing on liver cancer treatments, has announced its participation in two upcoming investor conferences. The company will attend the BTIG Virtual Biotechnology Conference on August 6, 2024, which will be held virtually. Additionally, Delcath will present at Canaccord Genuity's 44th Annual Growth Conference on August 14, 2024, at 9:30 am Eastern Time in Boston, MA.
These conferences provide Delcath Systems with opportunities to showcase its advancements in liver cancer treatment and engage with investors. The company's participation in both virtual and in-person events demonstrates its commitment to maintaining strong investor relations and promoting its innovative oncology solutions.
Delcath Systems (Nasdaq: DCTH), an interventional oncology company specializing in liver cancer treatments, has announced its upcoming second quarter 2024 earnings call. The call is scheduled for August 5, 2024, at 4:30 PM Eastern Time. Investors and interested parties can participate by dialing the provided toll-free or international numbers. A webcast of the call will also be available, with a replay accessible on the company's website shortly after the event concludes.
This earnings call will provide insights into Delcath's financial performance and operational updates for the quarter ended June 30, 2024. As a company focused on innovative liver cancer treatments, the call may offer valuable information on Delcath's progress in the oncology field and its market position.
Delcath Systems (Nasdaq: DCTH) reported its Q1 2024 financial results and business highlights on May 14, 2024. The company recognized $3.1 million in total revenue, a significant increase from $0.6 million in Q1 2023, driven by sales of HEPZATO KIT and CHEMOSAT. Delcath updated its U.S. center activation guidance to 20 by end of 2024, activated six new centers, and has five more preparing for activation. The company raised $7.0 million in a private placement and has cash reserves totaling $27.2 million.
Delcath appointed Martha S. Rook, Ph.D., as COO and received a permanent J-code and pass-through payment status for HEPZATO KIT from CMS effective April 1, 2024. Research and development expenses decreased to $3.7 million, while selling, general, and administrative expenses rose to $8.8 million, mainly due to commercial launch activities. The company also published pivotal Phase 3 FOCUS study results on HEPZATO KIT for treating unresectable metastatic Uveal Melanoma in the Annals of Surgical Oncology.
Delcath Systems, Inc. (Nasdaq: DCTH) will host a conference call on May 14, 2024, to discuss first quarter results. The company focuses on interventional oncology for liver cancers.
Delcath Systems, an interventional oncology company, announced positive results from the pivotal Phase 3 FOCUS study of HEPZATO KIT in patients with unresectable metastatic Uveal Melanoma. The study showed a significantly higher Overall Response Rate of 36.3% compared to historical controls, with a Disease Control Rate of 73.6% and a Complete Response Rate of 7.7%. Secondary endpoints included Duration of Response, Progression-free Survival, and Overall Survival. The study also reported comparable safety and tolerability with no treatment-related deaths.
Delcath Systems, Inc. (Nasdaq: DCTH) granted equity awards to two individuals as inducements for employment, totaling 33,000 shares of common stock, with an exercise price of $5.20. The options vest over a 24-month period and have a ten-year term, subject to continued employment.
FAQ
What is the current stock price of Delcath Sys (DCTH)?
What is the market cap of Delcath Sys (DCTH)?
